Video

CURE's Top Stories: January 2020

Take a look back at the top five CURE® stories for January 2020.

Here are the top five CURE® stories for January 2020.

5. Immunotherapy Vaccine Under Investigation

A new medication that aims to treat glioblastoma by using a patient’s own immune system will soon be available via a clinical trial this spring, according to researchers. Learn more in this story.

4. A Mother-Daughter Duo Believes in Hope

In this episode of the “CURE Talks Cancer” podcast, we spoke with breast cancer survivor Felicia Robinson, who recently wrote a book with her daughter on their personal experiences with a life-changing diagnosis.

3. The Falling, Wandering and Crashing of Treatment Side Effects

The bashing, the twitching, the gripping - here, CURE contributor Sherry Hanson explores the various neuropathy-related side effects she’s experienced as a result of her treatment for ovarian cancer.

2. Menopausal Hormone Therapy and Cancer

Women who took estrogen alone experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin. Take a closer look at the data from the San Antonio Breast Cancer Symposium in this piece.

1. Cognitive Dysfunction After Cancer

How do you heal your mind when faced with cognitive impairment after cancer treatment? Take a closer look at the new challenges one woman faces in the aftermath of the disease in this story.

As always, thanks for reading!

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content